Biotheranostics, Inc.

6 articles about Biotheranostics, Inc.

• Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

  3/5/2024

  Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced newly published study results revealing that use of the Breast Cancer Index® test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive breast cancer.

• Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer

  5/10/2021

  More women gain access to a test that helps determine whether extended endocrine therapy is appropriate for them

• Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million

  1/5/2021

  – Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –

• Biotheranostics Presents New Data on the Breast Cancer Index® at the San Antonio Breast Cancer Symposium

  12/7/2018

  Biotheranostics, Inc. announced the presentation of new data at the San Antonio Breast Cancer Symposium evaluating the impact of the Breast Cancer Index (BCI) in early stage hormone receptor positive (HR+) breast cancer patients classified as intermediate risk for distant recurrence by previous genomic testing.

• Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

  11/28/2018

  Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

• CancerTYPE® ID Prospective Trial Published in ASCO Journal of Precision Oncology

  3/19/2018

  Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of CancerTYPE ID on final diagnosis and treatment in patients with an unknown or unclear metastatic cancer diagnosis.